The Comprehensive Guide to Leuprolide 3.75mg Injection Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) is a premier pharmaceutical exporter from India, supplying high-quality Leuprolide 3.75mg Injection to healthcare providers, clinical distributors, and pharmacies globally, including London, the UK, the USA, Australia, and South Africa. Product Specifications Brand Name: Ernest-Oncology (Leuprolide Acetate) Strength: 3.75 mg Dosage Form: Depot / Extended-Release Injection (Intramuscular or Subcutaneous) Primary Indications: Prostate cancer, endometriosis, uterine fibroids, precocious puberty Storage: Store at room temperature (below 25°C), protect from light and moisture. Mechanism of Action Initial Stimulation: Following administration, it causes an initial, transient increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a brief increase in testosterone and estrogen levels (known as “flare“). Down-Regulation: With continuous use, the pituitary gland's receptors become desensitized. This leads to the downregulation of the GnRH receptors and suppression of LH and FSH. Hormone Suppression: Consequently, the production of testosterone in the testicles and estrogen in the ovaries is significantly reduced to near castrate levels. Therapeutic Indications & Administration Prostate Cancer: Palliative treatment of advanced, hormone-dependent prostate cancer to shrink the tumor and slow disease progression. Endometriosis: Management of endometriosis, including pain relief and the reduction of endometriotic lesions (typically used for a maximum of 6 months). Uterine Fibroids: Preoperative management used alongside iron therapy to shrink fibroids and treat anemia. Precocious Puberty: Slows down premature sexual development in pediatric patients. Administration: Administered exclusively under the supervision of a physician or nurse via intramuscular (IM) or subcutaneous (SC) injection, depending on the formulation protocol. Clinical Side Effects & Safety Profile Initial Flare Symptoms: Increased bone pain, urinary obstruction, or worsened endometriosis symptoms during the first few weeks of therapy. Common Effects: Hot flashes, increased sweating, fatigue, erectile dysfunction, decreased libido, and muscle weakness. Bone Mineral Density Loss: Prolonged use can cause a decrease in bone mineral density. Calcium and Vitamin D supplementation is recommended. Metabolic Changes: May worsen glycemic control in male diabetic patients; blood sugar must be monitored. Contraindications: Strictly contraindicated during pregnancy or breastfeeding due to potential fetal harm. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective oncology alternatives for private clinics and healthcare networks. USA: Delivering bulk supply solutions that adhere to strict quality and documentation standards. Australia: Providing reliable, compliant access to essential medications through established “Special Access Scheme“ (SAS) channels. South Africa: Bridging critical supply gaps with affordable, high-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.co www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us